AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...
MedImmune, the global biologics R&D arm of AstraZeneca, has acquired Spirogen in a deal worth up to US $440 million. Spirogen is a privately-held biotech focused on antibody-drug conjugate ...
The shift towards new cell culture–based flu vaccine production has been dealt a blow as MedImmune of Gaithersburg, Maryland, puts its manufacturing efforts on hold. The AstraZeneca subsidiary ...
Executive Vice President, R&D, MedImmune, Gaithersburg, Maryland, USA. Prior to joining Medimmune in 2001, Peter Kiener, D. Phil., spent 18 years with the Pharmaceutical Research Division of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results